Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

NCT02109406 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: AZD2115 Dose 1
DRUG: AZD 2115, Dose 2
DRUG: Placebo MDI

Sponsor

Pearl Therapeutics, Inc.